Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
NCT ID: NCT00060996
Last Updated: 2013-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
30 participants
INTERVENTIONAL
2003-02-28
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
NCT00067041
Safety Study of UT-15C SR (Oral Treprostinil) in Patients Undergoing a Lower Limb Endovascular Procedure
NCT00651885
Treatment for Blood Clots in the Veins of the Legs
NCT00001713
A Study of Modified Limb Braking and Early Bed Mobility Strategies After Femoral Venipuncture Intervention
NCT05900622
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects
NCT02949206
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remodulin® (treprostinil sodium) Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
United Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Wade, PhD
Role: STUDY_DIRECTOR
United Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of South Florida College of Medicine
Tampa, Florida, United States
University of Massachusetts Memorial Health
Worcester, Massachusetts, United States
Minneapolis Heart Institute
Minneapolis, Minnesota, United States
Oregon Health Sciences University
Portland, Oregon, United States
Presbyterian Medical Center, Philadelphia Heart Institute
Philadelphia, Pennsylvania, United States
South Carolina Heart Center
Columbia, South Carolina, United States
The Methodist Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REM 03:202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.